PL1873166T3 - Ulepszone dimery sgp 130Fc - Google Patents

Ulepszone dimery sgp 130Fc

Info

Publication number
PL1873166T3
PL1873166T3 PL06013668T PL06013668T PL1873166T3 PL 1873166 T3 PL1873166 T3 PL 1873166T3 PL 06013668 T PL06013668 T PL 06013668T PL 06013668 T PL06013668 T PL 06013668T PL 1873166 T3 PL1873166 T3 PL 1873166T3
Authority
PL
Poland
Prior art keywords
dimers
sgp
improved
dimer
molecules
Prior art date
Application number
PL06013668T
Other languages
English (en)
Inventor
Georg Wätzig
Dirk Seegert
Original Assignee
Conaris Res Institute Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Conaris Res Institute Ag filed Critical Conaris Res Institute Ag
Publication of PL1873166T3 publication Critical patent/PL1873166T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL06013668T 2006-06-30 2006-06-30 Ulepszone dimery sgp 130Fc PL1873166T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06013668A EP1873166B1 (en) 2006-06-30 2006-06-30 Improved sgp 130Fc dimers

Publications (1)

Publication Number Publication Date
PL1873166T3 true PL1873166T3 (pl) 2011-03-31

Family

ID=37654867

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06013668T PL1873166T3 (pl) 2006-06-30 2006-06-30 Ulepszone dimery sgp 130Fc

Country Status (21)

Country Link
US (3) US8895012B2 (pl)
EP (1) EP1873166B1 (pl)
JP (1) JP5417171B2 (pl)
KR (1) KR101474817B1 (pl)
CN (1) CN101484472B (pl)
AT (1) ATE480568T1 (pl)
AU (1) AU2007263939B2 (pl)
BR (1) BRPI0713063B8 (pl)
CA (1) CA2656440C (pl)
CY (1) CY1110973T1 (pl)
DE (1) DE602006016765D1 (pl)
DK (1) DK1873166T3 (pl)
EA (1) EA015620B1 (pl)
ES (1) ES2352561T3 (pl)
HR (1) HRP20100663T1 (pl)
PL (1) PL1873166T3 (pl)
PT (1) PT1873166E (pl)
RS (1) RS51544B (pl)
SI (1) SI1873166T1 (pl)
UA (1) UA95636C2 (pl)
WO (1) WO2008000516A2 (pl)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1873166T3 (pl) 2006-06-30 2011-03-31 Conaris Res Institute Ag Ulepszone dimery sgp 130Fc
CA3028038C (en) 2007-05-11 2021-08-10 Altor Bioscience Corporation Fusion molecules and il-15 variants
EP2050759A1 (en) * 2007-10-19 2009-04-22 CONARIS research institute AG Soluble gp 130 muteins with improved binding activity
EP4385570A3 (en) 2010-09-21 2024-09-11 Altor BioScience, LLC Multimeric il-15 soluble fusion molecules and methods of making and using same
US11053299B2 (en) 2010-09-21 2021-07-06 Immunity Bio, Inc. Superkine
KR101776542B1 (ko) * 2013-09-20 2017-09-19 인텔 코포레이션 Ap 위치 조회
PL3160498T3 (pl) 2014-06-30 2022-02-21 Altor Bioscience Corporation Cząsteczki na bazie IL-15 i sposoby ich zastosowania
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
CN107406491A (zh) 2014-12-01 2017-11-28 辉凌有限公司 选择性il‑6‑跨信号转导抑制剂组合物
SI3226888T1 (sl) 2014-12-01 2021-08-31 Ferring B.V. Dajanje selektivnega zaviralca signalizacije IL-6-trans
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
EP3455243B1 (en) 2016-05-11 2021-03-24 Cytiva BioProcess R&D AB Separation matrix
EP3455240B1 (en) 2016-05-11 2025-01-01 Cytiva BioProcess R&D AB Method of storing a separation matrix
CN109311948B (zh) 2016-05-11 2022-09-16 思拓凡生物工艺研发有限公司 清洁和/或消毒分离基质的方法
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
JP7031934B2 (ja) 2016-05-11 2022-03-08 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックス
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
US12448411B2 (en) 2016-09-30 2025-10-21 Cytiva Bioprocess R&D Ab Separation method
SG11201903306SA (en) 2016-10-21 2019-05-30 Altor Bioscience Corp Multimeric il-15-based molecules
CN108318689A (zh) * 2018-04-09 2018-07-24 北京大学深圳研究生院 一种多发性骨髓瘤的诊断方法
CN108593912A (zh) * 2018-04-09 2018-09-28 北京大学深圳研究生院 一种可溶性cd38浓度的检测方法
WO2020006469A1 (en) * 2018-06-29 2020-01-02 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods for treating and reducing traumatic brain injury-associated impairments using sgp130
GB2595299B (en) 2020-05-21 2022-08-03 Mabsolve Ltd Modified immunoglobulin FC regions
WO2021250069A1 (en) 2020-06-10 2021-12-16 Christian-Albrechts-Universität Zu Kiel Pharmaceutical compound for the treatment of atherosclerotic cardiovascular disease
TW202242142A (zh) 2020-12-22 2022-11-01 荷蘭商菲林公司 預測炎性腸病患者的響應之血液基因表現生物標誌物
CN114681592A (zh) * 2020-12-31 2022-07-01 天境生物科技(杭州)有限公司 包含可溶性gp130二聚体的制剂和使用方法
JP2024534211A (ja) * 2021-09-01 2024-09-18 テリックス ファーマシューティカルズ （イノベーションズ） ピーティーワイ リミテッド 凝集体分離方法
WO2024011946A1 (en) * 2022-07-12 2024-01-18 I-Mab Biopharma (Hangzhou) Co., Ltd Polypeptide dimers for the treatment of systemic sclerosis
EP4570816A1 (en) 2023-12-14 2025-06-18 Consejo Superior De Investigaciones Científicas - CSIC Soluble gp130fc (sgp130fc) for use in the treatment of sars-cov-2

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
JPH04218000A (ja) 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
WO1994012520A1 (en) 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
US5457035A (en) * 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US5783672A (en) 1994-05-26 1998-07-21 Immunex Corporation Receptor for oncostatin M
JP2002505086A (ja) * 1998-02-25 2002-02-19 レキシジェン ファーマシューティカルズ コーポレイション 抗体ベースの融合タンパク質の循環半減期の増強
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
DE19941897B4 (de) 1999-09-02 2006-06-14 GSF - Forschungszentrum für Umwelt und Gesundheit GmbH IL-6 Rezeptor-Protein, Beta-Kette (gp130) des IL-6 Rezeptor-Proteins, für diese Proteine kodierende DNA, davon abgeleitete RNA, Peptid mit den Aminosäuren 771-811 dieser Beta-Kette oder Teilen davon und deren Verwendungen
CN1406249B (zh) * 2000-02-11 2010-06-16 默克专利股份有限公司 增加基于抗体的融合蛋白的循环半衰期
PT1148065E (pt) * 2000-04-21 2008-04-03 Conaris Res Inst Ag Proteínas de fusão
AR033903A1 (es) 2001-05-21 2004-01-07 Inhale Therapeutic Syst Una composicion de insulina modificada quimicamente para la administracion pulmonar
WO2003008454A2 (en) * 2001-07-18 2003-01-30 Merck Patent Gmbh Glycoprotein vi fusion proteins
WO2003024389A2 (en) * 2001-07-30 2003-03-27 Immunex Corporation T. reesei phytase enyzmes, polynucleides encoding the enzymes, vectors and host cells thereof, and methods of using
DE602004011770T2 (de) * 2003-06-12 2009-02-05 Eli Lilly And Co., Indianapolis Fusionsproteine
EP1491554A1 (en) 2003-06-23 2004-12-29 CONARIS research institute AG PEGylated soluble gp130-dimers useful as a medicament
KR20060124656A (ko) * 2003-12-31 2006-12-05 메르크 파텐트 게엠베하 개선된 약물동태를 가지는 Ｆｃ-에리스로포이에틴 융합단백질
DE602004014758D1 (de) 2004-08-27 2008-08-14 Conaris Res Inst Ag Optimierte Nukleotidsequenzen die für sgp130 kodieren
EP1801121A1 (en) * 2005-12-23 2007-06-27 CONARIS research institute AG Soluble gp130 molecule variants useful as a medicament
PL1873166T3 (pl) 2006-06-30 2011-03-31 Conaris Res Institute Ag Ulepszone dimery sgp 130Fc

Also Published As

Publication number Publication date
HRP20100663T1 (hr) 2011-01-31
CN101484472B (zh) 2013-07-24
US8895012B2 (en) 2014-11-25
KR20090037898A (ko) 2009-04-16
CA2656440C (en) 2018-10-02
PT1873166E (pt) 2010-12-09
WO2008000516B1 (en) 2008-05-08
DE602006016765D1 (de) 2010-10-21
EP1873166A1 (en) 2008-01-02
US9034817B2 (en) 2015-05-19
CY1110973T1 (el) 2015-06-11
US20100028367A1 (en) 2010-02-04
BRPI0713063B8 (pt) 2021-05-25
WO2008000516A2 (en) 2008-01-03
US9573989B2 (en) 2017-02-21
RS51544B (sr) 2011-06-30
BRPI0713063B1 (pt) 2019-10-08
AU2007263939A1 (en) 2008-01-03
ES2352561T3 (es) 2011-02-21
JP5417171B2 (ja) 2014-02-12
CA2656440A1 (en) 2008-01-03
US20150361157A1 (en) 2015-12-17
JP2009540843A (ja) 2009-11-26
EP1873166B1 (en) 2010-09-08
EA200802396A1 (ru) 2009-06-30
ATE480568T1 (de) 2010-09-15
DK1873166T3 (da) 2010-12-20
UA95636C2 (en) 2011-08-25
WO2008000516A3 (en) 2008-03-27
SI1873166T1 (sl) 2011-01-31
BRPI0713063A2 (pt) 2012-04-17
KR101474817B1 (ko) 2014-12-22
EA015620B1 (ru) 2011-10-31
CN101484472A (zh) 2009-07-15
US20140178378A1 (en) 2014-06-26
AU2007263939B2 (en) 2011-11-24

Similar Documents

Publication Publication Date Title
SI1873166T1 (sl) IZBOLJĹ ANI sgp 130Fc DIMERJI
NZ592509A (en) HLA-A*1101-restricted WTI peptide and pharmaceutical composition comprising the same
DK1347730T4 (da) Rekombinante anti-CD30-antistoffer og anvendelser deraf
BRPI0406800B8 (pt) "dímero de peptídeo, composição farmacêutica contendo o mesmo e seu uso
NO20015584D0 (no) Lantidsvarende insulintrofiske peptider
ATE294817T1 (de) Concatamere immunadhäsion
CA2648109A1 (en) Combination of an anti-ed-b fibronectin domain antibody-il-2 fusion protein and gemcitabine
PE20091405A1 (es) Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf
WO2005001038A3 (en) Recombinant anti-cd30 antibodies and uses thereof
BRPI0511421A (pt) composições cosmética e farmacêutica para tratar materiais contendo queratina, uso de composições cosméticas, molécula efetora que liga queratina, uso da mesma, e, processo
WO2007120457A3 (en) Composition and method for stabilizing corneal tissue after refractive surgery
EP4249064A3 (en) Novel fusion protein specific for cd137 and pd-l1
WO2006113681A3 (en) Plant-derived elastin binding protein ligands and methods of using the same
BRPI0720879B8 (pt) microvesícula derivada de levedura carreadora de fator tissular (tf), composição e composição farmacêutica que a compreende e processos para a sua fabricação
WO2002048180A3 (de) Peptide und/oder proteine sowie verwendung desselben zur herstellung eines therapeutischen und/oder präventiven arzneimittels
DE602006017667D1 (de) Cysteinhaltiges peptid-tag zur stellenspezifischen konjugation von proteinen
WO2012078761A3 (en) Dimeric molecular complexes with free cysteine residues and conjugates thereof
MX337358B (es) Conjugados de disorazoles y sus derivados con moleculas de union con celulas, nuevos derivados de disorazol, procesos de fabricacion y usos de los mismos.
WO2006083964A3 (en) Modified fusion molecules for treatment of allergic disease
WO2008003707A3 (en) Minimized small peptides with high affinity for factor viii and factor viii-like proteins
BRPI0506148A (pt) preparação farmacêutica para o tratamento de choque
WO2008062158A3 (en) Polypeptide monomers and dimers containing mutated ilt
WO2008015344A3 (fr) Composition dermatologique et/ou cosmetique contenant des polypeptides ou des peptides issus de la proteine slc24a5
WO2007010285A3 (en) Crystal structure of human soluble adenylate cyclase
WO2008038296A3 (en) Recombinant calcitonin fused to interleukin-2